A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

Haisco Pharmaceutical Group

Status and phase

Enrolling

Phase 3

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Treatments

Drug: Ultibro 110μg/50 μg

Drug: HL231 Solution for Inhalation

Study type

Interventional

Funder types

Industry

Identifiers

NCT06643078

HEISCO-231-301

Details and patient eligibility

About

To evaluate the efficacy and safety of HL231 Solution for Inhalation vs Ultibro in Chinese patients with moderate to very severe COPD

Enrollment

474 estimated patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males and females of Chinese ethnicity, at least 40 years of age.
Patients with with a clinical diagnosis of moderate to severe COPD confirmed by spirometry according to according to GOLD criteria 2023.
Patients with a post-bronchodilator Forced Expiratory Volume in one second (FEV1) &lt; 80% of the predicted normal value, and post-bronchodilator FEV1/FVC (Forced Vital Capacity) &lt; 0.70 at visit 1.
Modified Medical Research Council (mMRC) grade of at least 2 at visit 1.

Exclusion criteria

Patients with any of the following diseases:α-1 antitrypsin deficiency, asthma, active pulmonary tuberculosis, lung cancer, pulmonary edema, cystic fibrosis, obliterated bronchiolitis, sarcoidosis, or other diseases that the investigator considers to be at risk of safety/efficacy for the patient, e.g lung fibrosis, pulmonary hypertension, interstitial lung disorder, active bronchiectasis.
Patients with a history of serious cardiovascular disease;
Patients with Type I or uncontrolled Type II diabetes;
Patients with paradoxical bronchospasm, narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (benign prostatic hyperplasia patients who were stable on treatment could have been considered), bladder-neck obstruction, severe renal impairment, or urinary retention, or any other medical history, which, in the opinion of the investigator, would contraindicate the use of an anticholinergic agent;
Patients who have had hospitalized due to COPD or pneumonia within 8 weeks prior to screening (Visit 1) or screening.
Patients who have had an acute (viral or bacterial) upper or lower respiratory tract infection, sinusitis, pharyngitis or urinary tract infections within 4 weeks prior to screening (Visit 1) or screening.
Patients who have had a COPD exacerbation that required treatment with systemic steroids, hospitalization or emergency treatment in the 8 weeks prior to screening (Visit 1).
Patients with conditions contraindicated for treatment with or having a history of allergy or hypersensitivity to any of the following inhaled drugs, drugs of a similar class or any component thereof: Anticholinergic/muscarinic receptor antagonist, Long- or short-acting β2-agonists, Sympathomimetic amines, Lactose/milk proteins, or any of the other excipients of the delivery system.

Other protocol-defined inclusion/exclusion criteria may apply.